{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:25:53Z","timestamp":1791861953609,"version":"4.3.4"},"reference-count":130,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRPIG-2023-0000845"],"award-info":[{"award-number":["IIRPIG-2023-0000845"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006593","name":"Board of Research in Nuclear Sciences","doi-asserted-by":"publisher","award":["202203HLC19RP07105-BRNS"],"award-info":[{"award-number":["202203HLC19RP07105-BRNS"]}],"id":[{"id":"10.13039\/501100006593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001857","name":"Technology Information, Forecasting and Assessment Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019305","name":"Manipal Academy of Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019305","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001502","name":"Department of Atomic Energy, Government of India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001502","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bbcan.2025.189504","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:06:25Z","timestamp":1764605185000},"page":"189504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Application of in vitro and in vivo cancer models to study the impact of the tumor immune microenvironment on anticancer therapy"],"prefix":"10.1016","volume":"1881","author":[{"given":"Rajat","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghu","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shama Prasada","family":"Kabekkodu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiban","family":"Chakrabarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/cai2.102","article-title":"A comprehensive review of 3D cancer models for drug screening and translational research","volume":"3","author":"Sharma","year":"2024","journal-title":"Cancer Innovation"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189504_bb0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"DiMasi","year":"2003","journal-title":"J. Health Econ."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12929-024-00997-9","article-title":"Modelling the complex nature of the tumor microenvironment: 3D tumor spheroids as an evolving tool","volume":"31","author":"Rodrigues","year":"2024","journal-title":"J. Biomed. Sci."},{"issue":"Suppl. 2","key":"10.1016\/j.bbcan.2025.189504_bb0025","article-title":"540 mouse models of anti-PD-1 resistance reveals insights into resistance mechanisms","volume":"12","author":"Fang","year":"2024","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/j.bbcan.2025.189504_bb0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev.pathol.3.121806.154244","article-title":"Mouse models of cancer","volume":"6","author":"Cheon","year":"2011","journal-title":"Annu. Rev. Pathol."},{"issue":"6917","key":"10.1016\/j.bbcan.2025.189504_bb0035","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"1075","key":"10.1016\/j.bbcan.2025.189504_bb0040","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/bmj.2.1075.198","article-title":"An address on the value of pathological experiments","volume":"2","author":"Virchow","year":"1881","journal-title":"Br. Med. J."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189504_bb0045","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41577-019-0271-z","article-title":"Immune crosstalk in cancer progression and metastatic spread: a complex conversation","volume":"20","author":"Garner","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bbcan.2025.189504_bb0060","doi-asserted-by":"crossref","first-page":"8126","DOI":"10.1038\/s41598-017-05326-9","article-title":"RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice","volume":"7","author":"Jahanban-Esfahlan","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189504_bb0065","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1002\/jcp.26051","article-title":"Combination of nanotechnology with vascular targeting agents for effective cancer therapy","volume":"233","author":"Jahanban-Esfahlan","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.canlet.2015.07.039","article-title":"Tumor microenvironment: sanctuary of the devil","volume":"368","author":"Hui","year":"2015","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189504_bb0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.bbcan.2025.189504_bb0080","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"Tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Current biology\u00a0: CB"},{"key":"10.1016\/j.bbcan.2025.189504_bb0085","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/216806","article-title":"Mechanisms of T-cell immunosuppression by mesenchymal stromal cells: what do we know so far?","volume":"2014","author":"Haddad","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0090","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cell.2012.04.042","article-title":"A CXCL1 paracrine network links cancer chemoresistance and metastasis","volume":"150","author":"Acharyya","year":"2012","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189504_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141602","article-title":"Tumor-associated endothelial cells promote tumor metastasis by chaperoning circulating tumor cells and protecting them from Anoikis","volume":"10","author":"Yadav","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189504_bb0100","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/nm.2492","article-title":"Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth","volume":"17","author":"Nieman","year":"2011","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189504_bb0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4252\/wjsc.v7.i2.253","article-title":"Hematopoietic stem cell-derived adipocytes and fibroblasts in the tumor microenvironment","volume":"7","author":"Xiong","year":"2015","journal-title":"World Journal of Stem Cells"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189504_bb0110","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1158\/0008-5472.CAN-10-3323","article-title":"Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion","volume":"71","author":"Dirat","year":"2011","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189504_bb0115","article-title":"Human adipocytes stimulate invasion of breast Cancer MCF-7 cells by secreting IGFBP-2","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2025.189504_bb0120","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13058-016-0740-2","article-title":"Tumor-associated stromal cells as key contributors to the tumor microenvironment","volume":"18","author":"Bussard","year":"2016","journal-title":"Breast Cancer Research\u00a0: BCR"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189504_bb0125","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ncb3157","article-title":"Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway","volume":"17","author":"Wei","year":"2015","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189504_bb0130","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/path.2278","article-title":"Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome","volume":"214","author":"Bergamaschi","year":"2008","journal-title":"J. Pathol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189504_bb0135","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/bcr3317","article-title":"High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes","volume":"14","author":"Riaz","year":"2012","journal-title":"Breast Cancer Research\u00a0: BCR"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189504_bb0140","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1158\/0008-5472.CAN-04-2463","article-title":"An expression signature classifies chemotherapy-resistant pediatric osteosarcoma","volume":"65","author":"Mintz","year":"2005","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189504_bb0150","first-page":"368","article-title":"A signature based on survival-related genes identifies high-risk glioblastomas harboring immunosuppressive and aggressive ECM characteristics","volume":"43","author":"Chen","year":"2018","journal-title":"Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189504_bb0155","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia","volume":"21","author":"Pylayeva-Gupta","year":"2012","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0160","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","article-title":"Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity","volume":"163","author":"Serrels","year":"2015","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189504_bb0170","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189504_bb0175","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189504_bb0180","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1073\/pnas.0931259100","article-title":"PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells","volume":"100","author":"Loke","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189504_bb0185","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tcb.2014.11.006","article-title":"Microenvironmental regulation of therapeutic response in cancer","volume":"25","author":"Klemm","year":"2015","journal-title":"Trends Cell Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tranon.2019.10.001","article-title":"Targeting tumor microenvironment by small-molecule inhibitors","volume":"13","author":"Zhong","year":"2020","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0195","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/s12964-024-01857-7","article-title":"Chemoresistance and the tumor microenvironment: the critical role of cell\u2013cell communication","volume":"22","author":"Wilczy\u0144ski","year":"2024","journal-title":"Cell Commun. Signal"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189504_bb0200","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ccr.2012.02.017","article-title":"Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance","volume":"21","author":"Nakasone","year":"2012","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189504_bb0205","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/0008-5472.CAN-12-3542","article-title":"Chemotherapy alters monocyte differentiation to favor generation of Cancer-supporting M2 macrophages in the tumor microenvironment","volume":"73","author":"Dijkgraaf","year":"2013","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189504_bb0210","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","article-title":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in Intratumoral dendritic cells","volume":"26","author":"Ruffell","year":"2014","journal-title":"Cancer Cell"},{"issue":"30","key":"10.1016\/j.bbcan.2025.189504_bb0215","doi-asserted-by":"crossref","first-page":"12425","DOI":"10.1073\/pnas.1106645108","article-title":"Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem\/initiating cells","volume":"108","author":"Jinushi","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"29","key":"10.1016\/j.bbcan.2025.189504_bb0220","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1038\/onc.2013.357","article-title":"Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase","volume":"33","author":"Weizman","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189504_bb0225","series-title":"Handbook of Oncobiology: From Basic to Clinical Sciences","first-page":"153","article-title":"History, evolution, and milestones in Cancer research and treatment","author":"Sharma","year":"2024"},{"key":"10.1016\/j.bbcan.2025.189504_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01300","article-title":"Evolution of Cancer pharmacological treatments at the turn of the third millennium","volume":"9","author":"Falzone","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"4873","key":"10.1016\/j.bbcan.2025.189504_bb0235","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1126\/science.2971269","article-title":"The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and Function","volume":"vol. 241","author":"McCune","year":"1988","journal-title":"Science (New York, N.Y.)"},{"issue":"5048","key":"10.1016\/j.bbcan.2025.189504_bb0240","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1126\/science.1372131","article-title":"Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice","volume":"vol. 255","author":"Lapidot","year":"1992","journal-title":"Science (New York, N.Y.)"},{"issue":"6187","key":"10.1016\/j.bbcan.2025.189504_bb0245","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/335256a0","article-title":"Transfer of a functional human immune system to mice with severe combined immunodeficiency","volume":"335","author":"Mosier","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189504_bb0250","series-title":"Handbook of Animal Models and its Uses in Cancer Research","first-page":"1","article-title":"Orthotopic PDX and CDX mice model for Cancer stem cell research","author":"Das","year":"2022"},{"issue":"18","key":"10.1016\/j.bbcan.2025.189504_bb0255","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.18632\/oncotarget.2373","article-title":"Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer","volume":"5","author":"Dobbin","year":"2014","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189504_bb0260","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/ijms21030962","article-title":"Establishment and characterisation by expression microarray of patient-derived xenograft panel of human pancreatic adenocarcinoma patients","volume":"21","author":"Roche","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189504_bb0265","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41467-022-29444-9","article-title":"Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes","volume":"13","author":"Mirhadi","year":"2022","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189504_bb0270","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/0008-5472.CAN-21-0799","article-title":"A microfluidic Cancer-on-Chip platform predicts drug response using Organotypic tumor slice culture","volume":"82","author":"Chakrabarty","year":"2022","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189504_bb0275","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/jpm10030064","article-title":"Patient-derived tumor xenograft models: toward the establishment of precision Cancer medicine","volume":"10","author":"Goto","year":"2020","journal-title":"Journal of Personalized Medicine"},{"issue":"17","key":"10.1016\/j.bbcan.2025.189504_bb0280","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.3390\/cancers15174352","article-title":"Challenges and prospects of patient-derived xenografts for Cancer research","volume":"15","author":"Jin","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189504_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.gendis.2025.101520","article-title":"Patient-derived xenograft models: current status, challenges, and innovations in cancer research","volume":"12","author":"Liu","year":"2025","journal-title":"Genes & Diseases"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189504_bb0290","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708662","article-title":"Innovations, challenges, and minimal information for standardization of humanized mice","volume":"12","author":"Stripecke","year":"2020","journal-title":"EMBO Mol. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189504_bb0295","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","article-title":"Humanized mouse models for immuno-oncology research","volume":"20","author":"Chuprin","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189504_bb0300","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.693","article-title":"Establishing a microfluidic tumor slice culture platform to study drug response","volume":"3","author":"Komar","year":"2023","journal-title":"Current Protocols"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189504_bb0305","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3390\/cancers14051252","article-title":"Functional ex vivo tissue-based chemotherapy sensitivity testing for breast Cancer","volume":"14","author":"Ladan","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2025.189504_bb0310","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12885-016-2119-2","article-title":"Tumor slice culture system to assess drug response of primary breast cancer","volume":"16","author":"Naipal","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0315","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12885-019-5465-z","article-title":"A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform","volume":"19","author":"Riley","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-020-0117-y","article-title":"Multiplexed drug testing of tumor slices using a microfluidic platform","volume":"4","author":"Horowitz","year":"2020","journal-title":"npj Precision Oncology"},{"key":"10.1016\/j.bbcan.2025.189504_bb0325","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13619-020-00059-z","article-title":"Organoid based personalized medicine: from bench to bedside","volume":"9","author":"Li","year":"2020","journal-title":"Cell Regeneration"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189504_bb0330","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.stem.2018.11.016","article-title":"Human intestinal organoids maintain self-renewal capacity and cellular diversity in niche-inspired culture condition","volume":"23","author":"Fujii","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189504_bb0335","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","article-title":"Organoids in cancer research","volume":"18","author":"Drost","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189504_bb0340","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12885-018-4238-4","article-title":"Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models","volume":"18","author":"Tsai","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189504_bb0345","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1248","article-title":"Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro","volume":"10","author":"Yu","year":"2021","journal-title":"Clinical & Translational Immunology"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189504_bb0350","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/cimb47080653","article-title":"Immune organoids: a review of their applications in Cancer and autoimmune disease immunotherapy","volume":"47","author":"Olawade","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.bbcan.2025.189504_bb0355","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-bioeng-082420-124920","article-title":"Modeling immunity in vitro: slices, chips and engineered tissues","volume":"23","author":"Hammel","year":"2021","journal-title":"Annu. Rev. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0360","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41591-020-01145-0","article-title":"Modeling human adaptive immune responses with tonsil organoids","volume":"27","author":"Wagar","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189504_bb0365","series-title":"Cancer Biomarkers: Methods and Protocols","first-page":"133","article-title":"Air\u2013liquid Interface culture model to study lung Cancer-associated cellular and molecular changes","author":"Agraval","year":"2022"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189504_bb0370","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189504_bb0375","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.3389\/fonc.2020.01775","article-title":"Cultivation of clear cell renal cell carcinoma patient-derived organoids in an air-liquid Interface system as a tool for studying individualized therapy","volume":"10","author":"Esser","year":"2020","journal-title":"Front. Oncol."},{"issue":"40","key":"10.1016\/j.bbcan.2025.189504_bb0380","doi-asserted-by":"crossref","first-page":"66747","DOI":"10.18632\/oncotarget.19965","article-title":"Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures","volume":"8","author":"Finnberg","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189504_bb0385","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201604630","article-title":"Rapid continuous multi-material extrusion bioprinting","volume":"29","author":"Liu","year":"2017","journal-title":"Advanced Materials (Deerfield Beach, Fla.)"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189504_bb0390","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1039\/D1LC00003A","article-title":"The acoustic droplet printing of functional tumor microenvironments","volume":"21","author":"Chen","year":"2021","journal-title":"Lab Chip"},{"issue":"22","key":"10.1016\/j.bbcan.2025.189504_bb0395","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202101312","article-title":"Acoustic droplet printing tumor organoids for modeling bladder tumor immune microenvironment within a week","volume":"10","author":"Gong","year":"2021","journal-title":"Adv. Healthc. Mater."},{"issue":"7839","key":"10.1016\/j.bbcan.2025.189504_bb0400","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-020-3034-x","article-title":"Creation of bladder assembloids mimicking tissue regeneration and cancer","volume":"588","author":"Kim","year":"2020","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.bbcan.2025.189504_bb0405","article-title":"3D-bioprinted Mini-brain: a glioblastoma model to study cellular interactions and therapeutics","volume":"31","author":"Heinrich","year":"2019","journal-title":"Advanced Materials (Deerfield Beach, Fla.)"},{"key":"10.1016\/j.bbcan.2025.189504_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2019.100658","article-title":"Three dimensional in vitro models of cancer: bioprinting multilineage glioblastoma models","volume":"75","author":"Hermida","year":"2020","journal-title":"Adv. Biol. Regulation"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0415","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41467-024-45147-9","article-title":"A 3D printable tissue adhesive","volume":"15","author":"Wu","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0420","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41467-024-45147-9","article-title":"A 3D printable tissue adhesive","volume":"15","author":"Wu","year":"2024","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189504_bb0425","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1039\/b921695b","article-title":"Microfluidic cell culture systems for drug research","volume":"10","author":"Wu","year":"2010","journal-title":"Lab Chip"},{"issue":"23","key":"10.1016\/j.bbcan.2025.189504_bb0430","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.3390\/cancers13236052","article-title":"Going with the flow: modeling the tumor microenvironment using microfluidic technology","volume":"13","author":"Xie","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189504_bb0435","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201903739","article-title":"A droplet microfluidic system to fabricate hybrid capsules enabling stem cell organoid engineering","volume":"7","author":"Liu","year":"2020","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bbcan.2025.189504_bb0440","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41378-022-00370-6","article-title":"Patient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment","volume":"8","author":"Haque","year":"2022","journal-title":"Microsyst. Nanoeng."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189504_bb0445","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1158\/2159-8290.CD-17-0833","article-title":"Ex vivo profiling of PD-1 blockade using Organotypic tumor spheroids","volume":"8","author":"Jenkins","year":"2018","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189504_bb0450","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments anti-tumor immunity by enhancing T cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189504_bb0455","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/bit.25950","article-title":"A reductionist metastasis-on-a-chip platform for in vitro tumor progression modeling and drug screening","volume":"113","author":"Skardal","year":"2016","journal-title":"Biotechnol. Bioeng."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189504_bb0460","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/mi9100493","article-title":"Microfluidic-based 3D engineered microvascular networks and their applications in vascularized microtumor models","volume":"9","author":"Wang","year":"2018","journal-title":"Micromachines"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189504_bb0465","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.drudis.2020.03.002","article-title":"Organotypic cancer tissue models for drug screening: 3D constructs, bioprinting and microfluidic chips","volume":"25","author":"Radhakrishnan","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189504_bb0470","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.stem.2022.04.006","article-title":"Patient-derived micro-organospheres (MOS) enable clinical precision oncology","volume":"29","author":"Ding","year":"2022","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189504_bb0475","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.drudis.2016.11.009","article-title":"Organs-on-chips: research and commercial perspectives","volume":"22","author":"Balijepalli","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189504_bb0480","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nbt.2989","article-title":"Microfluidic organs-on-chips","volume":"32","author":"Bhatia","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-021-02526-y","article-title":"Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response","volume":"4","author":"Petreus","year":"2021","journal-title":"Communications Biology"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189504_bb0490","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s41403-020-00148-0","article-title":"Prototype of a Smart Microfluidic Platform for the Evaluation of SARS-Cov-2 Pathogenesis, Along with Estimation of the Effectiveness of Potential Drug Candidates and Antigen\u2013Antibody Interactions in Convalescent Plasma Therapy","volume":"5","author":"Roy","year":"2020","journal-title":"Transactions of the Indian National Academy of Engineering"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189504_bb0495","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrm1858","article-title":"Capturing complex 3D tissue physiology in vitro","volume":"7","author":"Griffith","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189504_bb0500","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1039\/c2ib00176d","article-title":"Organs-on-chips: breaking the in vitro impasse","volume":"4","author":"van der Meer","year":"2012","journal-title":"Integr. Biol."},{"issue":"7491","key":"10.1016\/j.bbcan.2025.189504_bb0505","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nature13118","article-title":"The present and future role of microfluidics in biomedical research","volume":"507","author":"Sackmann","year":"2014","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189504_bb0510","doi-asserted-by":"crossref","DOI":"10.1063\/1.4935594","article-title":"An optically transparent membrane supports shear stress studies in a three-dimensional microfluidic neurovascular unit model","volume":"9","author":"Sellgren","year":"2015","journal-title":"Biomicrofluidics"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0515","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1038\/ncomms3718","article-title":"Tumour-on-a-chip provides an optical window into nanoparticle tissue transport","volume":"4","author":"Albanese","year":"2013","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189504_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188717","article-title":"Organ-on-Chip platforms to study tumor evolution and chemosensitivity","volume":"1877","author":"Dsouza","year":"2022","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189504_bb0525","doi-asserted-by":"crossref","first-page":"E2293","DOI":"10.1073\/pnas.1612906114","article-title":"Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189504_bb0530","article-title":"Biofabrication strategies for creating microvascular complexity","volume":"11","author":"Clyne","year":"2019","journal-title":"Biofabrication"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0535","doi-asserted-by":"crossref","first-page":"14886","DOI":"10.1038\/s41598-019-51494-1","article-title":"Modeling living cells within microfluidic systems using cellular automata models","volume":"9","author":"Ballesteros Hernando","year":"2019","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189504_bb0540","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1039\/c2lc40089h","article-title":"Microengineered physiological biomimicry: organs-on-chips","volume":"12","author":"Huh","year":"2012","journal-title":"Lab Chip"},{"key":"10.1016\/j.bbcan.2025.189504_bb0545","series-title":"Methods in Cell Biology","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/bs.mcb.2018.09.007","article-title":"Chapter 1 - viable cell culture in PDMS-based microfluidic devices","volume":"vol. 148","author":"Tanyeri","year":"2018"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189504_bb0550","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s10439-012-0562-z","article-title":"Quantitative analysis of molecular absorption into PDMS microfluidic channels","volume":"40","author":"Wang","year":"2012","journal-title":"Ann. Biomed. Eng."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189504_bb0555","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbrc.2016.11.062","article-title":"Small molecule absorption by PDMS in the context of drug response bioassays","volume":"482","author":"van Meer","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189504_bb0560","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jbiosc.2018.10.019","article-title":"Glass-based organ-on-a-chip device for restricting small molecular absorption","volume":"127","author":"Hirama","year":"2019","journal-title":"J. Biosci. Bioeng."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189504_bb0570","first-page":"365","article-title":"Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development","volume":"37","author":"Marx","year":"2020","journal-title":"ALTEX - Alternatives to animal experimentation"},{"issue":"497","key":"10.1016\/j.bbcan.2025.189504_bb0575","doi-asserted-by":"crossref","first-page":"eaav1386","DOI":"10.1126\/scitranslmed.aav1386","article-title":"Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics","volume":"11","author":"McAleer","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189504_bb0580","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3390\/mi11040381","article-title":"Drug toxicity evaluation based on organ-on-a-chip Technology: A review","volume":"11","author":"Cong","year":"2020","journal-title":"Micromachines"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189504_bb0585","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1039\/C9LC00811J","article-title":"A microfluidic platform for functional testing of cancer drugs on intact tumor slices","volume":"20","author":"Rodriguez","year":"2020","journal-title":"Lab Chip"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0590","doi-asserted-by":"crossref","first-page":"6327","DOI":"10.1038\/s41598-019-42745-2","article-title":"A patient tumour-on-a-chip system for personalised investigation of radiotherapy based treatment regimens","volume":"9","author":"Kennedy","year":"2019","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189504_bb0595","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of Talimogene Laherparepvec in combination with Ipilimumab versus Ipilimumab alone in patients with advanced, Unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189504_bb0600","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189504_bb0605","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189504_bb0610","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus Pemetrexed and platinum in nonsquamous non-small-cell lung Cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189504_bb0615","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung Cancer treated with Atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189504_bb0620","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung Cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.bbcan.2025.189504_bb0625","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1186\/s12885-023-11203-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study","volume":"23","author":"Tokito","year":"2024","journal-title":"BMC Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.bbcan.2025.189504_bb0630","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1186\/s12885-023-10971-7","article-title":"A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679\/ECHO-302)","volume":"23","author":"Lara","year":"2024","journal-title":"BMC Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.bbcan.2025.189504_bb0635","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1186\/s12885-022-10427-4","article-title":"Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study","volume":"23","author":"Boyer","year":"2024","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189504_bb0640","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","article-title":"Bempegaldesleukin (NKTR-214) plus Nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02)","volume":"10","author":"Diab","year":"2020","journal-title":"Cancer Discov."},{"issue":"19","key":"10.1016\/j.bbcan.2025.189504_bb0645","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-20-1170","article-title":"Talimogene Laherparepvec and Pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY-232): a multicenter, phase 1b study","volume":"26","author":"Harrington","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2025.189504_bb0650","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1200\/JCO.2017.35.15_suppl.9510","article-title":"Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma","volume":"35","author":"Andtbacka","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189504_bb0655","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11523-021-00809-2","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with esophageal adenocarcinoma: results from a phase 1 cohort","volume":"16","author":"Tan","year":"2021","journal-title":"Target. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.bbcan.2025.189504_bb0660","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1186\/s12885-023-11316-0","article-title":"Pembrolizumab plus epacadostat in patients with recurrent\/metastatic head and neck squamous cell carcinoma (KEYNOTE-669\/ECHO-304): a phase 3, randomized, open-label study","volume":"23","author":"Cho","year":"2024","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189504_bb0665","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41416-023-02267-1","article-title":"Phase I\/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors","volume":"128","author":"Luke","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.bbcan.2025.189504_bb0670","doi-asserted-by":"crossref","first-page":"P181","DOI":"10.1186\/2051-1426-3-S2-P181","article-title":"A phase I\/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)","volume":"3","author":"Long","year":"2015","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189504_bb0675","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s11912-024-01611-9","article-title":"Talimogene laherparepvec (T-VEC) and emerging Intralesional immunotherapies for metastatic melanoma: a review","volume":"26","author":"Kalsi","year":"2024","journal-title":"Curr. Oncol. Rep."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X2500246X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X2500246X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:04:27Z","timestamp":1768910667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X2500246X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0304419X2500246X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189504","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of in vitro and in vivo cancer models to study the impact of the tumor immune microenvironment on anticancer therapy","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189504"}}